VenstraMedical Raises Funding for pVAD Program Development

December 1, 2025—VenstraMedical announced that it has received a strategic investment from Highcroft Capital, a Minnesota-based venture capital firm specializing in early-stage MedTech innovation.

According to the company, the investment will accelerate development of VenstraMedical’s next-generation percutaneous ventricular assist device (pVAD). It will progress the VenstraMedical pVAD program toward first-in-human clinical trials.

The company noted that it also recently secured a $1 million grant from MTPConnect’s Targeted Translation Research Accelerator—part of Australia’s Medical Research Future Fund—to advance its development pathway.

VenstraMedical’s pVAD is a low-profile, full-flow cardiac support system designed to provide complete ventricular unloading for critically ill cardiac patients. The company stated that the device aims to deliver minimally invasive circulatory support in both cardiogenic shock and high-risk coronary interventions.

The Highcroft investment comes after the publication of VenstraMedical’s preclinical results by Martin C. Cook, PhD, et al in ASAIO and their presentation at the TCT 2025 scientific symposium. Dr. Cook is cofounder and CEO of VenstraMedical, noted the press release.